论文部分内容阅读
目的:探讨养胃舒、叶酸片治疗亚硝基胍(MNNG)诱发慢性萎缩性胃炎(CAG)模型大鼠的体重恢复及胃黏膜萎缩逆转作用。方法:Wistar大鼠自由饮用167μg/ml蒸馏水浓度的饮用液,实验造模12周。确定成模后,将大鼠分为模型组、养胃舒组、叶酸片组,另设同龄正常对照组。并分别给予药物干预后,观察大鼠体重、胃组织病理组织学情况。结果:(1)体重:治疗第8周,养胃舒组体重丢失恢复显著高于模型组(P<0.05),叶酸片组体重丢失有恢复趋势,但无显著性(P>0.05)。(2)病理:养胃舒组肠化显著减轻(P<0.05),叶酸片组胃黏膜炎症等级、腺体萎缩、不典型增生均显著减轻(P<0.05,P<0.01)。模型组雄1发生肿瘤,各治疗组未见肿瘤。结论:养胃舒对CAG模型大鼠在减轻体重丢失,减轻肠化方面有较好治疗作用;叶酸片对CAG模型大鼠在胃黏膜炎症等级、腺体萎缩、不典型增生方面有较好的治疗作用。
Objective: To investigate the effects of Yangwei Shu and folic acid tablets on weight loss and gastric mucosal atrophy in rats with chronic atrophic gastritis (CAG) induced by nitroguanidine (MNNG). Methods: Wistar rats were given free drinking solution of 167 μg / ml distilled water for 12 weeks. After establishing the model, the rats were divided into model group, Yangwei Shu group, folic acid tablets group, and another normal control group at the same age. After given the drug intervention respectively, the body weight and pathological histology of the rats were observed. Results: (1) Body weight: At the 8th week of treatment, the weight loss recovery of Yangweishu group was significantly higher than that of the model group (P <0.05). The body weight loss of the folic acid tablets group showed a trend of recovery but no significant difference (P> 0.05). (2) Pathology: The intestinal metaplasia of Yangwei Shu group was significantly reduced (P <0.05). The levels of gastric mucosal inflammation, glandular atrophy and dysplasia were significantly decreased in folic acid tablets group (P <0.05, P <0.01). Tumor in the model group male 1, no tumor in each treatment group. Conclusion: Yangwei Shu has a good therapeutic effect on reducing weight loss and reducing intestinal metaplasia in CAG model rats. Folic acid tablets have good effects on gastric mucosal inflammation, glandular atrophy and atypical hyperplasia in CAG model rats Therapeutic effect.